[go: up one dir, main page]

PE20230682A1 - Anticuerpo anti-ox40 y usos del mismo - Google Patents

Anticuerpo anti-ox40 y usos del mismo

Info

Publication number
PE20230682A1
PE20230682A1 PE2022002226A PE2022002226A PE20230682A1 PE 20230682 A1 PE20230682 A1 PE 20230682A1 PE 2022002226 A PE2022002226 A PE 2022002226A PE 2022002226 A PE2022002226 A PE 2022002226A PE 20230682 A1 PE20230682 A1 PE 20230682A1
Authority
PE
Peru
Prior art keywords
antibody
antigen
fragment
binds
seq
Prior art date
Application number
PE2022002226A
Other languages
English (en)
Inventor
Yizhen Yang
Yu Cai
Xiong Li
Lei Zhou
Weiguo Qing
Wei-Guo Su
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of PE20230682A1 publication Critical patent/PE20230682A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)

Abstract

Referido a un anticuerpo anti-OX40 aislado o un fragmento que se une a antigeno del mismo, que comprende: (1) uno a tres seleccionados entre HCDR1, HCDR2 y HCDR3 de una region variable de cadena pesada (VH), donde la secuencia de aminoacidos de la VH es como se indica en la SEQ ID NO: 1, 2, 3, 4 o 5; y/o (2) uno a tres seleccionados entre LCDR1, LCDR2 y LCDR3 de una region variable de cadena liviana (VL), donde la secuencia de aminoacidos de la VL es como se indica en la SEQ ID NO: 6, 7, 8, 9 o 10. Tambien se refiere a un acido nucleico aislado, que codifica el anticuerpo o fragmento que se une a antigeno, un vector recombinante o un vector de expresion, una celula huesped, que comprende uno o mas vectores recombinantes o vectores de expresion, un inmunoconjugado o una fusion inmune, que comprende el anticuerpo o fragmento que se une, una composicion farmaceutica que comprende el anticuerpo o fragmento que se une a antigeno, metodo de preparacion de una droga y su uso para tratar o prevenir un cancer, tal como melanoma, preferentemente melanoma metastasico.
PE2022002226A 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo PE20230682A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010304381 2020-04-17
PCT/CN2021/087617 WO2021209020A1 (en) 2020-04-17 2021-04-16 Anti-ox40 antibody and uses thereof

Publications (1)

Publication Number Publication Date
PE20230682A1 true PE20230682A1 (es) 2023-04-21

Family

ID=78084656

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022002227A PE20230255A1 (es) 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo
PE2022002226A PE20230682A1 (es) 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2022002227A PE20230255A1 (es) 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo

Country Status (16)

Country Link
US (3) US20230242657A1 (es)
EP (2) EP4136116A4 (es)
JP (2) JP2023523395A (es)
KR (2) KR20230015328A (es)
CN (2) CN115461366B (es)
AR (2) AR121857A1 (es)
AU (2) AU2021256799A1 (es)
BR (2) BR112022020741A2 (es)
CA (2) CA3175407A1 (es)
CL (2) CL2022002830A1 (es)
IL (2) IL297294A (es)
MX (2) MX2022012915A (es)
PE (2) PE20230255A1 (es)
PH (2) PH12022552725A1 (es)
TW (2) TWI877350B (es)
WO (2) WO2021209019A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461366B (zh) * 2020-04-17 2025-11-11 和记黄埔医药（上海）有限公司 抗ox40抗体及其用途
WO2025021131A1 (en) * 2023-07-25 2025-01-30 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Methods of treating alopecia areata and atopic dermatitis
WO2025161898A1 (en) * 2024-02-02 2025-08-07 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ox40 antibodies and uses thereof
WO2025185555A1 (en) * 2024-03-04 2025-09-12 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Pharmaceutical compositions comprising ox40 targeting antibodies and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5426300A (en) 1993-09-17 1995-06-20 Leybold Inficon, Inc. Portable GCMS system using getter pump
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
KR100887482B1 (ko) 1999-01-15 2009-03-10 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2851374B1 (en) 2007-12-14 2017-05-03 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
EA036047B1 (ru) 2011-07-11 2020-09-18 Икнос Сайенсиз Са Антитела, которые связываются с ox40, и их применение
US20150322119A1 (en) 2012-12-03 2015-11-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
CN106103486B (zh) 2014-03-31 2020-04-21 豪夫迈·罗氏有限公司 抗ox40抗体和使用方法
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
SG11201708804WA (en) * 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
AU2016274585A1 (en) * 2015-06-08 2017-12-14 Genentech, Inc. Methods of treating cancer using anti-OX40 antibodies
CN114380908B (zh) * 2015-10-15 2023-03-17 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
BR122020025629B1 (pt) * 2016-12-15 2022-05-31 Abbvie Biotherapeutics Inc Anticorpo anti-ox40, composição farmacêutica que compreende o mesmo e método in vitro para a produção do dito anticorpo
WO2019028182A2 (en) * 2017-08-01 2019-02-07 Remd Biotherapeutics, Inc. TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
JP2021501801A (ja) * 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
EP3713958A4 (en) * 2017-11-24 2021-11-03 Eucure (Beijing) Biopharma Co., Ltd ANTI-OX40 ANTIBODIES AND USES THEREOF
CN110092832B (zh) * 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 抗ox40抗体及其用途
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
BR112020023746A2 (pt) 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico
CN110003338B (zh) * 2019-04-16 2021-04-23 北京免疫方舟医药科技有限公司 抗ox40抗体及其应用
CN110004177A (zh) * 2019-04-22 2019-07-12 中国食品药品检定研究院 一种检测抗ox40抗体的方法及其应用
CN115461366B (zh) * 2020-04-17 2025-11-11 和记黄埔医药（上海）有限公司 抗ox40抗体及其用途
TW202323280A (zh) * 2021-10-15 2023-06-16 新加坡商創響私人有限公司 包含抗－ｏｘ４０單株抗體的藥物製劑

Also Published As

Publication number Publication date
US20240301077A1 (en) 2024-09-12
MX2022012913A (es) 2022-11-14
AR121858A1 (es) 2022-07-20
MX2022012915A (es) 2022-11-16
PH12022552741A1 (en) 2024-02-12
AR121857A1 (es) 2022-07-20
KR20230015327A (ko) 2023-01-31
PH12022552725A1 (en) 2023-01-04
CN115461366B (zh) 2025-11-11
WO2021209020A1 (en) 2021-10-21
WO2021209019A1 (en) 2021-10-21
CA3175413A1 (en) 2021-10-21
KR20230015328A (ko) 2023-01-31
AU2021256226A1 (en) 2022-11-17
US12030951B2 (en) 2024-07-09
CN115461367A (zh) 2022-12-09
IL297294A (en) 2022-12-01
EP4136116A4 (en) 2024-06-19
EP4136116A1 (en) 2023-02-22
EP4136117A4 (en) 2024-04-10
US20230151105A1 (en) 2023-05-18
AU2021256799A1 (en) 2022-11-17
TW202144424A (zh) 2021-12-01
JP2023521475A (ja) 2023-05-24
TWI877350B (zh) 2025-03-21
EP4136117A1 (en) 2023-02-22
JP2023523395A (ja) 2023-06-05
BR112022020741A2 (pt) 2022-12-20
US20230242657A1 (en) 2023-08-03
JP7760525B2 (ja) 2025-10-27
CL2022002829A1 (es) 2023-06-09
IL297292A (en) 2022-12-01
CL2022002830A1 (es) 2023-06-09
TW202144423A (zh) 2021-12-01
TWI873332B (zh) 2025-02-21
BR112022020742A2 (pt) 2022-12-20
CA3175407A1 (en) 2021-10-21
PE20230255A1 (es) 2023-02-07
CN115461366A (zh) 2022-12-09

Similar Documents

Publication Publication Date Title
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
PE20240363A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20220218A1 (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
AR123480A1 (es) Moléculas de unión terapéuticas
PE20191079A1 (es) Inmunoglobulinas y usos de estas
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
PE20240086A1 (es) Anticuerpos anti-cd122 y usos de estos
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR100573A1 (es) Anticuerpos anti-il-17, un método para producirlos y utilizarlos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CO2018001256A2 (es) Anticuerpos anti-cd154 y métodos para producir los mismos
AR123083A1 (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
PE20240802A1 (es) Anticuerpos multiespecificos con especificidad para il-4r e il-31
AR103713A1 (es) Anticuerpos contra tau y sus usos
PE20141706A1 (es) Anticuerpos de union a trombina y usos del mismo